Literature DB >> 16487216

Rare diseases and orphan drugs.

J K Aronson.   

Abstract

Mesh：

Year:  2006        PMID： 16487216      PMCID： PMC1885017          DOI： 10.1111/j.1365-2125.2006.02617.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

Review 1.  Two decades of orphan product development.

Authors:  Marlene E Haffner; Janet Whitley; Marie Moses
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

2.  Application of tissue culture methods to epidemiological studies of poliomyelitis.

Authors:  J L MELNICK
Journal:  Am J Public Health Nations Health       Date:  1954-05

3.  Orphan drug development is progressing too slowly.

Authors:  Roberta Joppi; Vittorio Bertele; Silvio Garattini
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 4.  The orphan opioid receptor and its endogenous ligand--nociceptin/orphanin FQ.

Authors:  G Henderson; A T McKnight
Journal:  Trends Pharmacol Sci       Date:  1997-08       Impact factor: 14.819

Review 5.  A review of alcohol clearance in humans.

Authors:  W E Lands
Journal:  Alcohol       Date:  1998-02       Impact factor: 2.405

6.  Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

Authors:  C T Dooley; C G Spaeth; I P Berzetei-Gurske; K Craymer; I D Adapa; S R Brandt; R A Houghten; L Toll
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

Review 7.  Orphan drugs: legal aspects, current situation.

Authors:  A Lavandeira
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

Review 8.  HGV: the identification, biology and prevalence of an orphan virus.

Authors:  M J Mphahlele; G K Lau; W F Carman
Journal:  Liver       Date:  1998-06

9.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728
View more
  23 in total

Review 1.  The medicines for children agenda in the UK.

Authors:  Terence Stephenson
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

2.  Orphan drug development is not taking off.

Authors:  Roberta Joppi; Vittorio Bertele; Silvio Garattini
Journal:  Br J Clin Pharmacol       Date:  2009-01-21       Impact factor: 4.335

3.  Study and analysis of the state of rare disease research in Shandong Province, China.

Authors:  Heng Zhao; Yazhou Cui; Xiaoyan Zhou; Jingxiang Pang; Xiumei Zhang; Shuangqing Xu; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2012-11

Review 4.  Access to orphan drugs in the Middle East: Challenge and perspective.

Authors:  Ziyad S Almalki; Abdullah K Alahmari; Jeff J Guo; Christina M L Kelton
Journal:  Intractable Rare Dis Res       Date:  2012-11

Review 5.  National information system for rare diseases with an approach to data architecture: A systematic review.

Authors:  Simin Derayeh; Alireza Kazemi; Reza Rabiei; Azamossadat Hosseini; Hamid Moghaddasi
Journal:  Intractable Rare Dis Res       Date:  2018-08

6.  Early Recognition and Management of Rare Kidney Stone Disorders.

Authors:  Boss Goldstein; David S Goldfarb
Journal:  Urol Nurs       Date:  2017 Mar-Apr

7.  Drugs for rare disorders.

Authors:  Serge Cremers; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2017-06-27       Impact factor: 4.335

8.  A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs.

Authors:  Yazhou Cui; Jinxiang Han
Journal:  Orphanet J Rare Dis       Date:  2015-03-07       Impact factor: 4.123

9.  Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension.

Authors:  Howard H Z Thom; Gorana Capkun; Annamaria Cerulli; Richard M Nixon; Luke S Howard
Journal:  BMC Med Res Methodol       Date:  2015-04-12       Impact factor: 4.615

Review 10.  Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.

Authors:  Julie Winstone; Shkun Chadda; Stephen Ralston; Peter Sajosi
Journal:  Orphanet J Rare Dis       Date:  2015-10-28       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.